

# Accepted Manuscript

Successful treatment of severe psoriasis relapse with Secukinumab(IL17 A inhibitor) after abrupt Brodalumab (IL17 receptor inhibitor) discontinuation: A retrospective study evaluating long term efficacy and safety

Abdallah Khemis, MD, Awatef Kelati, MD, Henri Montaudié, MD, Jean-Philippe Lacour, MD, Thierry Passeron, MD, PhD

PII: S0190-9622(18)30479-1

DOI: [10.1016/j.jaad.2018.03.027](https://doi.org/10.1016/j.jaad.2018.03.027)

Reference: YMJD 12416

To appear in: *Journal of the American Academy of Dermatology*

Received Date: 8 October 2017

Revised Date: 19 February 2018

Accepted Date: 14 March 2018

Please cite this article as: Khemis A, Kelati A, Montaudié H, Lacour J-P, Passeron T, Successful treatment of severe psoriasis relapse with Secukinumab(IL17 A inhibitor) after abrupt Brodalumab (IL17 receptor inhibitor) discontinuation: A retrospective study evaluating long term efficacy and safety, *Journal of the American Academy of Dermatology* (2018), doi: 10.1016/j.jaad.2018.03.027.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



1 **Successful treatment of severe psoriasis relapse with Secukinumab(IL17 A inhibitor)**  
2 **after abrupt Brodalumab (IL17 receptor inhibitor) discontinuation: A retrospective**  
3 **study evaluating long term efficacy and safety**  
4  
5

6 Abdallah Khemis <sup>1</sup>, MD, Awatef Kelati <sup>1</sup>, MD, Henri Montaudié <sup>1</sup>, MD, Jean-Philippe Lacour  
7 <sup>1</sup>, MD, Thierry Passeron <sup>1,2</sup>, MD, PhD

8 1 Université Nice Côte d'Azur. Centre Hospitalier Universitaire Nice. Department of  
9 Dermatology. Nice, France.

10 2 Université Nice Côte d'Azur. INSERM U1065, C3M, team 12. Nice, France

11 **Corresponding author**

12 Professor Thierry Passeron MD PhD

13 Department of Dermatology.

14 Hôpital de l'Archet 2, CHU de Nice

15 150 route de Ginestière 06202, Nice France

16 Phone: +33 4 92 03 64 88, fax: +33 4 92 03 65 60, email: [passeron@unice.fr](mailto:passeron@unice.fr)

17 **Conflict of interest disclosures:**

18 Drs Khemis, Lacour and Passeron have been investigators with Amgen, Abbvie, Celgene,  
19 Janssen, LEO pharma, Lilly, MSD, Novartis, Pfizer, UCB pharma.

20 Dr Khemis has received honoraria and travel expenses from Abbvie, Amgen, Janssen,  
21 Celgene, LEO pharma, Lilly, MSD, Novartis, Pfizer, UCB pharma.

22 Dr Lacour has received honoraria and travel expenses from Abbvie, Amgen, Janssen,  
23 Celgene, LEO pharma, Lilly, MSD, Novartis, Pfizer, UCB pharma.

24 Dr Passeron has received honoraria and travel expenses from Abbvie, Celgene, Janssen, LEO  
25 pharma, Lilly, MSD, Novartis, Pfizer.

26 Dr Montaudié has received honoraria and travel expenses from Abbvie, Celgene, Lilly,  
27 Merck, Pfizer, ROCHE, BMS

28  
29 **Funding sources for the work:** None

30 **Word count :** 500

31 **Figure count :** 1

32 **Table count :** 1

Download English Version:

<https://daneshyari.com/en/article/10216833>

Download Persian Version:

<https://daneshyari.com/article/10216833>

[Daneshyari.com](https://daneshyari.com)